Cargando…

Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults

BACKGROUND: In spring 2020, at the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Europe, we set up an assay system for large-scale testing of virus-specific and neutralising antibodies including their longevity. METHODS: We analysed the sera of 1655 adult...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagner, Angelika, Guzek, Angela, Ruff, Johanna, Jasinska, Joanna, Scheikl, Ute, Zwazl, Ines, Kundi, Michael, Stockinger, Hannes, Farcet, Maria R., Kreil, Thomas R., Hoeltl, Eva, Wiedermann, Ursula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037317/ https://www.ncbi.nlm.nih.gov/pubmed/35602189 http://dx.doi.org/10.1038/s43856-021-00012-4

Ejemplares similares

SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year
por: Garner-Spitzer, Erika, et al.
Publicado: (2022)

Obesity and Sex Affect the Immune Responses to Tick-Borne Encephalitis Booster Vaccination
por: Garner-Spitzer, Erika, et al.
Publicado: (2020)

Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
por: Richter, Lukas, et al.
Publicado: (2019)

Correction: Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
por: Richter, Lukas, et al.
Publicado: (2019)

Lack of seroprotection against diphtheria in the Austrian population, in light of reported diphtheria cases in Europe, 2022
por: Wagner, Angelika, et al.
Publicado: (2023)

Full seroconversion in initial non-responders with higher antibody levels after heterologous COVID-19 vaccination schedule.
por: Wagner, Angelika, et al.
Publicado: (2022)

Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules
por: Wagner, Angelika, et al.
Publicado: (2018)

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants
por: Carnell, George W., et al.
Publicado: (2023)

Preexisting anti-PF4 antibodies are not further triggered upon vaccination with SARS-CoV-2 vector vaccines in a cohort of 400 health care workers
por: Angelika, Wagner, et al.
Publicado: (2022)

SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease
por: Wagner, Angelika, et al.
Publicado: (2022)

2356. Close correlation of RBD with Live Viral Neutralising Capacity Across Variants and Time Supports Use of RBD Thresholds to Predict Protective Host Immunity
por: Kenny, Grace, et al.
Publicado: (2023)

Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide
por: Tobias, Joshua, et al.
Publicado: (2017)

Absent antibody production following COVID19 vaccination with mRNA in patients under immunosuppressive treatments
por: Wagner, Angelika, et al.
Publicado: (2021)

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant
por: Singanallur, Nagendrakumar B., et al.
Publicado: (2022)

Vaccine based on folded RBD‐PreS fusion protein with potential to induce sterilizing immunity to SARS‐CoV‐2 variants
por: Gattinger, Pia, et al.
Publicado: (2022)

Function matters: Coronavirus cross-binding antibodies do not cross-neutralize
por: Farcet, Maria R., et al.
Publicado: (2022)

No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic
por: Schwaiger, Julia, et al.
Publicado: (2020)

Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic( )
por: Farcet, Maria R, et al.
Publicado: (2021)

Feasibility of identifying plasma donors with high measles neutralizing antibody concentrations for the use of producing a measles hyperimmune globulin for postexposure prophylaxis
por: Lackner, Cornelia, et al.
Publicado: (2022)

Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe( )
por: Farcet, Maria R, et al.
Publicado: (2022)

Prime-Boost Vaccination with Toxoplasma Lysate Antigen, but Not with a Mixture of Recombinant Protein Antigens, Leads to Reduction of Brain Cyst Formation in BALB/c Mice
por: Wagner, Angelika, et al.
Publicado: (2015)

Oocyst-Derived Extract of Toxoplasma Gondii Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy
por: Wagner, Angelika, et al.
Publicado: (2016)

Neutralisation and the brickwall
por: Hereward, H G
Publicado: (1974)

Virus Neutralisation: New Insights from Kinetic Neutralisation Curves
por: Magnus, Carsten
Publicado: (2013)

Detergent-Mediated Virus Inactivation in Biotechnological Matrices: More than Just CMC
por: Farcet, Jean-Baptiste, et al.
Publicado: (2023)

Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies
por: Tani, Chiara, et al.
Publicado: (2021)

Mechanisms of Rhinovirus Neutralisation by Antibodies
por: Touabi, Lila, et al.
Publicado: (2021)

Synthesis of “Nereid,” a new phenol‐free detergent to replace Triton X‐100 in virus inactivation
por: Farcet, Jean‐Baptiste, et al.
Publicado: (2020)

SARS-CoV-2 and the safety margins of cell-based biological medicinal products
por: Modrof, Jens, et al.
Publicado: (2020)

Electron cooling with neutralised electron beams
por: Bosser, J, et al.
Publicado: (1994)

The Role of Alveolar Epithelial Type II-Like Cells in Uptake of Structurally Different Antigens and in Polarisation of Local Immune Responses
por: Akgün, Johnnie, et al.
Publicado: (2015)

Electron cooling with neutralised electron beams
por: Bosser, Jacques, et al.
Publicado: (1994)

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines
por: Karbiener, Michael, et al.
Publicado: (2022)

Neutralisation pockets and spectral lines
por: Gröbner, Oswald
Publicado: (1972)

On Toxic Neutralisations: II. Reconstitution
por: Richardson, Benjamin Ward
Publicado: (1894)

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations
por: Jungbauer, Christof, et al.
Publicado: (2020)

Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-α-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation
por: Garner-Spitzer, Erika, et al.
Publicado: (2023)

Neutralisation and servo-system on the LEAR electron cooler
por: Bosser, J, et al.
Publicado: (1993)

Neutralisation and servo-system on the LEAR electron cooler
por: Bosser, Jacques, et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_8a5tl7qim0rc8don568n7bo0j9